Athira Pharma, Inc.

NasdaqGS:ATHA Voorraadrapport

Marktkapitalisatie: US$23.3m

Athira Pharma Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Athira Pharma's earnings have been declining at an average annual rate of -47%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually.

Belangrijke informatie

-47.0%

Groei van de winst

-17.9%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie6.0%
Inkomstengroein/a
Rendement op eigen vermogen-136.1%
Nettomargen/a
Laatste winstupdate30 Jun 2024

Recente prestatie-updates uit het verleden

Geen updates

Recent updates

Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?

Feb 16
Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Nov 02
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

May 29
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?

Jan 04
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?

Athira Alzheimer's drug trial gets monitoring panel nod to continue after efficacy analysis

Oct 17

Athira Pharma GAAP EPS of -$0.65

Aug 15

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Aug 09
We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug

Jun 22

Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth

May 08
Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth

We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate

Jan 11
We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate

Athira Pharma: What, Exactly, Did The CEO Do?

Jun 29

Athira Pharma falls after the decision to place CEO on temporary leave

Jun 17

Athira surges after Jefferies estimated 50% gain on FDA approval for Biogen’s Alzheimer’s therapy

Jun 07

We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth

May 24
We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Feb 08
We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Athira: Early Stage Alzheimer's Therapeutics With An Interesting Approach

Jan 11

Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like

Dec 18
Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like

Athira Pharma nabs research grant of $15M from NIH

Dec 08

Athira Pharma reports Q3 results

Nov 12

Opbrengsten en kosten

Hoe Athira Pharma geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NasdaqGS:ATHA Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 240-1132794
31 Mar 240-1163194
31 Dec 230-1183394
30 Sep 230-1213485
30 Jun 230-1083375
31 Mar 230-1023268
31 Dec 220-963361
30 Sep 220-823159
30 Jun 220-773153
31 Mar 220-672750
31 Dec 210-552143
30 Sep 210-461935
30 Jun 210-391330
31 Mar 210-27920
31 Dec 200-20713
30 Sep 200-1339
30 Jun 200-624
31 Mar 200-623
31 Dec 190-524

Kwaliteitswinsten: ATHA is currently unprofitable.

Groeiende winstmarge: ATHA is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: ATHA is unprofitable, and losses have increased over the past 5 years at a rate of 47% per year.

Versnelling van de groei: Unable to compare ATHA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: ATHA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).


Rendement op eigen vermogen

Hoge ROE: ATHA has a negative Return on Equity (-136.14%), as it is currently unprofitable.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden